# Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

**Authors:** Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno

PMC · DOI: 10.1186/s12933-024-02190-6 · Cardiovascular Diabetology · 2024-03-18

## Full-text entities

- **Chemicals:** empagliflozin (MESH:C570240)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10949568/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10949568/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC10949568/full.md

---
Source: https://tomesphere.com/paper/PMC10949568